Emerging Strategies of Cancer Therapy Based on Ferroptosis

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

<p class="first" id="P1">Ferroptosis, a new form of regulated cell death that is iron- and reactive oxygen species (ROS)-dependent, has attracted much attention in the research communities of biochemistry, oncology, and especially the material sciences. Since the first demonstration by Stockwell <i>et al.</i> in 2012, a series of strategies have been developed to induce ferroptosis of cancer cells, including the use of nanomaterials, clinical drugs, experimental compounds, and genes. A plethora of research work has outlined the blueprint of ferroptosis as a new option for cancer therapy. However, the published ferroptosis related reviews have mainly focused on the mechanisms and pathways of ferroptosis, which motivated us to contribute a review to bridge the gap between biological significance and material design. Therefore, it is timely to summarize the previous efforts on the emerging strategies for inducing ferroptosis and shed light on future directions for using such a tool to fight against cancer. In this review, we will elaborate on the current strategies of cancer therapy based on ferroptosis, highlight the design considerations and the advantages and limitations, and finally give a future perspective on this emerging field. </p>

Related collections

Most cited references 46

Record: found
Abstract: found
Article: not found

ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition.

Sebastian Doll, Bettina Proneth, Yulia Tyurina … (2017)

Ferroptosis is a form of regulated necrotic cell death controlled by glutathione peroxidase 4 (GPX4). At present, mechanisms that could predict sensitivity and/or resistance and that may be exploited to modulate ferroptosis are needed. We applied two independent approaches-a genome-wide CRISPR-based genetic screen and microarray analysis of ferroptosis-resistant cell lines-to uncover acyl-CoA synthetase long-chain family member 4 (ACSL4) as an essential component for ferroptosis execution. Specifically, Gpx4-Acsl4 double-knockout cells showed marked resistance to ferroptosis. Mechanistically, ACSL4 enriched cellular membranes with long polyunsaturated ω6 fatty acids. Moreover, ACSL4 was preferentially expressed in a panel of basal-like breast cancer cell lines and predicted their sensitivity to ferroptosis. Pharmacological targeting of ACSL4 with thiazolidinediones, a class of antidiabetic compound, ameliorated tissue demise in a mouse model of ferroptosis, suggesting that ACSL4 inhibition is a viable therapeutic approach to preventing ferroptosis-related diseases.

0 comments Cited 1462 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Ferroptosis: process and function.

Y Xie, W Hou, X Song … (2016)

Ferroptosis is a recently recognized form of regulated cell death. It is characterized morphologically by the presence of smaller than normal mitochondria with condensed mitochondrial membrane densities, reduction or vanishing of mitochondria crista, and outer mitochondrial membrane rupture. It can be induced by experimental compounds (e.g., erastin, Ras-selective lethal small molecule 3, and buthionine sulfoximine) or clinical drugs (e.g., sulfasalazine, sorafenib, and artesunate) in cancer cells and certain normal cells (e.g., kidney tubule cells, neurons, fibroblasts, and T cells). Activation of mitochondrial voltage-dependent anion channels and mitogen-activated protein kinases, upregulation of endoplasmic reticulum stress, and inhibition of cystine/glutamate antiporter is involved in the induction of ferroptosis. This process is characterized by the accumulation of lipid peroxidation products and lethal reactive oxygen species (ROS) derived from iron metabolism and can be pharmacologically inhibited by iron chelators (e.g., deferoxamine and desferrioxamine mesylate) and lipid peroxidation inhibitors (e.g., ferrostatin, liproxstatin, and zileuton). Glutathione peroxidase 4, heat shock protein beta-1, and nuclear factor erythroid 2-related factor 2 function as negative regulators of ferroptosis by limiting ROS production and reducing cellular iron uptake, respectively. In contrast, NADPH oxidase and p53 (especially acetylation-defective mutant p53) act as positive regulators of ferroptosis by promotion of ROS production and inhibition of expression of SLC7A11 (a specific light-chain subunit of the cystine/glutamate antiporter), respectively. Misregulated ferroptosis has been implicated in multiple physiological and pathological processes, including cancer cell death, neurotoxicity, neurodegenerative diseases, acute renal failure, drug-induced hepatotoxicity, hepatic and heart ischemia/reperfusion injury, and T-cell immunity. In this review, we summarize the regulation mechanisms and signaling pathways of ferroptosis and discuss the role of ferroptosis in disease.

0 comments Cited 1405 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels.

Nicholas Yagoda, Moritz von Rechenberg, Elma Zaganjor … (2007)

Therapeutics that discriminate between the genetic makeup of normal cells and tumour cells are valuable for treating and understanding cancer. Small molecules with oncogene-selective lethality may reveal novel functions of oncoproteins and enable the creation of more selective drugs. Here we describe the mechanism of action of the selective anti-tumour agent erastin, involving the RAS-RAF-MEK signalling pathway functioning in cell proliferation, differentiation and survival. Erastin exhibits greater lethality in human tumour cells harbouring mutations in the oncogenes HRAS, KRAS or BRAF. Using affinity purification and mass spectrometry, we discovered that erastin acts through mitochondrial voltage-dependent anion channels (VDACs)--a novel target for anti-cancer drugs. We show that erastin treatment of cells harbouring oncogenic RAS causes the appearance of oxidative species and subsequent death through an oxidative, non-apoptotic mechanism. RNA-interference-mediated knockdown of VDAC2 or VDAC3 caused resistance to erastin, implicating these two VDAC isoforms in the mechanism of action of erastin. Moreover, using purified mitochondria expressing a single VDAC isoform, we found that erastin alters the permeability of the outer mitochondrial membrane. Finally, using a radiolabelled analogue and a filter-binding assay, we show that erastin binds directly to VDAC2. These results demonstrate that ligands to VDAC proteins can induce non-apoptotic cell death selectively in some tumour cells harbouring activating mutations in the RAS-RAF-MEK pathway.

0 comments Cited 640 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Journal

Title: Advanced Materials

Abbreviated Title: Adv. Mater.

Publisher: Wiley

ISSN: 09359648

Publication date Created: March 2018

Publication date (Print): March 2018

Publication date (Electronic): January 22 2018

Volume: 30

Issue: 12

Page: 1704007

Affiliations

[1 ]CAS Key Laboratory of Magnetic Materials and Devices; Key Laboratory of Additive Manufacturing Materials of Zhejiang Province; Division of Functional Materials and Nanodevices; Ningbo Institute of Materials Technology and Engineering; Chinese Academy of Sciences; 1219 ZhongGuan West Road Ningbo Zhejiang 315201 China

[2 ]Laboratory of Molecular Imaging and Nanomedicine; National Institute of Biomedical Imaging and Bioengineering; National Institutes of Health; Bethesda MD 20892 USA